Generic Drugs for Multiple Cancers Market - Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: GE2419B3F400EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Generic Drugs for Multiple Cancers in Global, including the following market information:

Global Generic Drugs for Multiple Cancers Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Generic Drugs for Multiple Cancers market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Cytotoxic Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Generic Drugs for Multiple Cancers include Pfizer, GlaxoSmithKline, Novartis, Merck, Celgene, Teva Pharmaceutical, Mylan, Aurobindo Pharma and Hikma Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Generic Drugs for Multiple Cancers companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Generic Drugs for Multiple Cancers Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Generic Drugs for Multiple Cancers Market Segment Percentages, by Type, 2021 (%)

• Cytotoxic Drug
• Noncytotoxic Drugs

Global Generic Drugs for Multiple Cancers Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Generic Drugs for Multiple Cancers Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacy
• Retail Pharmacies
• Online Pharmacies

Global Generic Drugs for Multiple Cancers Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Generic Drugs for Multiple Cancers Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Generic Drugs for Multiple Cancers revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Generic Drugs for Multiple Cancers revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• GlaxoSmithKline
• Novartis
• Merck
• Celgene
• Teva Pharmaceutical
• Mylan
• Aurobindo Pharma
• Hikma Pharmaceuticals
• Roche
• Redsenol

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Generic Drugs for Multiple Cancers Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Generic Drugs for Multiple Cancers Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GENERIC DRUGS FOR MULTIPLE CANCERS OVERALL MARKET SIZE

2.1 Global Generic Drugs for Multiple Cancers Market Size: 2021 VS 2028
2.2 Global Generic Drugs for Multiple Cancers Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Generic Drugs for Multiple Cancers Players in Global Market
3.2 Top Global Generic Drugs for Multiple Cancers Companies Ranked by Revenue
3.3 Global Generic Drugs for Multiple Cancers Revenue by Companies
3.4 Top 3 and Top 5 Generic Drugs for Multiple Cancers Companies in Global Market, by Revenue in 2021
3.5 Global Companies Generic Drugs for Multiple Cancers Product Type
3.6 Tier 1, Tier 2 and Tier 3 Generic Drugs for Multiple Cancers Players in Global Market
  3.6.1 List of Global Tier 1 Generic Drugs for Multiple Cancers Companies
  3.6.2 List of Global Tier 2 and Tier 3 Generic Drugs for Multiple Cancers Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Generic Drugs for Multiple Cancers Market Size Markets, 2021 & 2028
  4.1.2 Cytotoxic Drug
  4.1.3 Noncytotoxic Drugs
4.2 By Type - Global Generic Drugs for Multiple Cancers Revenue & Forecasts
  4.2.1 By Type - Global Generic Drugs for Multiple Cancers Revenue, 2017-2022
  4.2.2 By Type - Global Generic Drugs for Multiple Cancers Revenue, 2023-2028
  4.2.3 By Type - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Generic Drugs for Multiple Cancers Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacy
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Generic Drugs for Multiple Cancers Revenue & Forecasts
  5.2.1 By Application - Global Generic Drugs for Multiple Cancers Revenue, 2017-2022
  5.2.2 By Application - Global Generic Drugs for Multiple Cancers Revenue, 2023-2028
  5.2.3 By Application - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Generic Drugs for Multiple Cancers Market Size, 2021 & 2028
6.2 By Region - Global Generic Drugs for Multiple Cancers Revenue & Forecasts
  6.2.1 By Region - Global Generic Drugs for Multiple Cancers Revenue, 2017-2022
  6.2.2 By Region - Global Generic Drugs for Multiple Cancers Revenue, 2023-2028
  6.2.3 By Region - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Generic Drugs for Multiple Cancers Revenue, 2017-2028
  6.3.2 US Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.3.3 Canada Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.3.4 Mexico Generic Drugs for Multiple Cancers Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Generic Drugs for Multiple Cancers Revenue, 2017-2028
  6.4.2 Germany Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.3 France Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.4 U.K. Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.5 Italy Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.6 Russia Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.7 Nordic Countries Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.4.8 Benelux Generic Drugs for Multiple Cancers Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Generic Drugs for Multiple Cancers Revenue, 2017-2028
  6.5.2 China Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.5.3 Japan Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.5.4 South Korea Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.5.5 Southeast Asia Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.5.6 India Generic Drugs for Multiple Cancers Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Generic Drugs for Multiple Cancers Revenue, 2017-2028
  6.6.2 Brazil Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.6.3 Argentina Generic Drugs for Multiple Cancers Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Generic Drugs for Multiple Cancers Revenue, 2017-2028
  6.7.2 Turkey Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.7.3 Israel Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.7.4 Saudi Arabia Generic Drugs for Multiple Cancers Market Size, 2017-2028
  6.7.5 UAE Generic Drugs for Multiple Cancers Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Generic Drugs for Multiple Cancers Major Product Offerings
  7.1.4 Pfizer Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 GlaxoSmithKline
  7.2.1 GlaxoSmithKline Corporate Summary
  7.2.2 GlaxoSmithKline Business Overview
  7.2.3 GlaxoSmithKline Generic Drugs for Multiple Cancers Major Product Offerings
  7.2.4 GlaxoSmithKline Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.2.5 GlaxoSmithKline Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Generic Drugs for Multiple Cancers Major Product Offerings
  7.3.4 Novartis Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Merck
  7.4.1 Merck Corporate Summary
  7.4.2 Merck Business Overview
  7.4.3 Merck Generic Drugs for Multiple Cancers Major Product Offerings
  7.4.4 Merck Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.4.5 Merck Key News
7.5 Celgene
  7.5.1 Celgene Corporate Summary
  7.5.2 Celgene Business Overview
  7.5.3 Celgene Generic Drugs for Multiple Cancers Major Product Offerings
  7.5.4 Celgene Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.5.5 Celgene Key News
7.6 Teva Pharmaceutical
  7.6.1 Teva Pharmaceutical Corporate Summary
  7.6.2 Teva Pharmaceutical Business Overview
  7.6.3 Teva Pharmaceutical Generic Drugs for Multiple Cancers Major Product Offerings
  7.6.4 Teva Pharmaceutical Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.6.5 Teva Pharmaceutical Key News
7.7 Mylan
  7.7.1 Mylan Corporate Summary
  7.7.2 Mylan Business Overview
  7.7.3 Mylan Generic Drugs for Multiple Cancers Major Product Offerings
  7.7.4 Mylan Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.7.5 Mylan Key News
7.8 Aurobindo Pharma
  7.8.1 Aurobindo Pharma Corporate Summary
  7.8.2 Aurobindo Pharma Business Overview
  7.8.3 Aurobindo Pharma Generic Drugs for Multiple Cancers Major Product Offerings
  7.8.4 Aurobindo Pharma Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.8.5 Aurobindo Pharma Key News
7.9 Hikma Pharmaceuticals
  7.9.1 Hikma Pharmaceuticals Corporate Summary
  7.9.2 Hikma Pharmaceuticals Business Overview
  7.9.3 Hikma Pharmaceuticals Generic Drugs for Multiple Cancers Major Product Offerings
  7.9.4 Hikma Pharmaceuticals Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.9.5 Hikma Pharmaceuticals Key News
7.10 Roche
  7.10.1 Roche Corporate Summary
  7.10.2 Roche Business Overview
  7.10.3 Roche Generic Drugs for Multiple Cancers Major Product Offerings
  7.10.4 Roche Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.10.5 Roche Key News
7.11 Redsenol
  7.11.1 Redsenol Corporate Summary
  7.11.2 Redsenol Business Overview
  7.11.3 Redsenol Generic Drugs for Multiple Cancers Major Product Offerings
  7.11.4 Redsenol Generic Drugs for Multiple Cancers Revenue in Global Market (2017-2022)
  7.11.5 Redsenol Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Generic Drugs for Multiple Cancers Market Opportunities & Trends in Global Market
Table 2. Generic Drugs for Multiple Cancers Market Drivers in Global Market
Table 3. Generic Drugs for Multiple Cancers Market Restraints in Global Market
Table 4. Key Players of Generic Drugs for Multiple Cancers in Global Market
Table 5. Top Generic Drugs for Multiple Cancers Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Generic Drugs for Multiple Cancers Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Generic Drugs for Multiple Cancers Revenue Share by Companies, 2017-2022
Table 8. Global Companies Generic Drugs for Multiple Cancers Product Type
Table 9. List of Global Tier 1 Generic Drugs for Multiple Cancers Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Generic Drugs for Multiple Cancers Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Generic Drugs for Multiple Cancers Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Generic Drugs for Multiple Cancers Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Generic Drugs for Multiple Cancers Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Generic Drugs for Multiple Cancers Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Generic Drugs for Multiple Cancers Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Generic Drugs for Multiple Cancers Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Generic Drugs for Multiple Cancers Product Offerings
Table 32. Pfizer Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 33. GlaxoSmithKline Corporate Summary
Table 34. GlaxoSmithKline Generic Drugs for Multiple Cancers Product Offerings
Table 35. GlaxoSmithKline Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Generic Drugs for Multiple Cancers Product Offerings
Table 38. Novartis Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 39. Merck Corporate Summary
Table 40. Merck Generic Drugs for Multiple Cancers Product Offerings
Table 41. Merck Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 42. Celgene Corporate Summary
Table 43. Celgene Generic Drugs for Multiple Cancers Product Offerings
Table 44. Celgene Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 45. Teva Pharmaceutical Corporate Summary
Table 46. Teva Pharmaceutical Generic Drugs for Multiple Cancers Product Offerings
Table 47. Teva Pharmaceutical Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 48. Mylan Corporate Summary
Table 49. Mylan Generic Drugs for Multiple Cancers Product Offerings
Table 50. Mylan Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 51. Aurobindo Pharma Corporate Summary
Table 52. Aurobindo Pharma Generic Drugs for Multiple Cancers Product Offerings
Table 53. Aurobindo Pharma Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 54. Hikma Pharmaceuticals Corporate Summary
Table 55. Hikma Pharmaceuticals Generic Drugs for Multiple Cancers Product Offerings
Table 56. Hikma Pharmaceuticals Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 57. Roche Corporate Summary
Table 58. Roche Generic Drugs for Multiple Cancers Product Offerings
Table 59. Roche Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)
Table 60. Redsenol Corporate Summary
Table 61. Redsenol Generic Drugs for Multiple Cancers Product Offerings
Table 62. Redsenol Generic Drugs for Multiple Cancers Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Generic Drugs for Multiple Cancers Segment by Type in 2021
Figure 2. Generic Drugs for Multiple Cancers Segment by Application in 2021
Figure 3. Global Generic Drugs for Multiple Cancers Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Generic Drugs for Multiple Cancers Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Generic Drugs for Multiple Cancers Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Generic Drugs for Multiple Cancers Revenue in 2021
Figure 8. By Type - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 9. By Application - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 10. By Region - Global Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 11. By Country - North America Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 12. US Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 16. Germany Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 17. France Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 24. China Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 28. India Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 30. Brazil Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Generic Drugs for Multiple Cancers Revenue Market Share, 2017-2028
Figure 33. Turkey Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Generic Drugs for Multiple Cancers Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. GlaxoSmithKline Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Celgene Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Teva Pharmaceutical Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Mylan Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Aurobindo Pharma Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Hikma Pharmaceuticals Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Roche Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Redsenol Generic Drugs for Multiple Cancers Revenue Year Over Year Growth (US$, Mn) & (2017-2022)